Join to View Full Profile
975 Park AveNew York, NY 10028
Phone+1 212-772-9305
Fax+1 212-772-2247
Dr. Tuchman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Alan Tuchman is a neurologist based in New York, NY, with a comprehensive educational background that includes an internship at Metropolitan Medical Center and a neurology residency at Icahn School of Medicine at Mount Sinai. He earned his medical degree from the University of Cincinnati College of Medicine in 1972. Dr. Tuchman is currently Clinical Professor of Neurology at New York Medical College. Dr. Tuchman has been recognized for his expertise by being named one of Castle Connolly's Top Doctors in the New York Metro Area from 2002 to 2024. His research work includes multiple publications, notably studies on Alzheimer's disease, AIDS-related central nervous system involvement, and complications related to cocaine use, with several articles receiving numerous citations. Additionally, he is involved in clinical trials, such as studying the use of intratumoral REOLYSIN® with chemotherapy as a treatment for bladder cancer.
Education & Training
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Neurology, 1973 - 1976
Lincoln Medical and Mental Health CenterInternship, Transitional Year, 1972 - 1973
University of Cincinnati College of MedicineClass of 1972
Certifications & Licensure
NY State Medical License 1973 - 2026
NJ State Medical License 1978 - 1991
OH State Medical License 1976 - 1979
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2002-2014
Clinical Trials
Publications & Presentations
PubMed
- 7 citationsAdvanced Alzheimer's Disease Patients Show Safe, Significant, and Persistent Benefit in 6-Month Bryostatin Trial.Daniel L Alkon, Miao-Kun Sun, Alan J Tuchman, Richard E Thompson
Journal of Alzheimer's Disease. 2023-01-01 - 12 citationsBryostatin Placebo-Controlled Trials Indicate Cognitive Restoration Above Baseline for Advanced Alzheimer's Disease in the Absence of Memantine1.Richard E Thompson, Alan J Tuchman, Daniel L Alkon
Journal of Alzheimer's Disease. 2022-01-01 - 50 citationsA Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Seve...Martin R. Farlow, Richard E. Thompson, Lee-Jen Wei, Alan J. Tuchman, Elaine Grenier
Journal of Alzheimer's Disease. 2019-01-01
Press Mentions
Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease TrialApril 19th, 2022- Synaptogenix to Present at Upcoming Scientific Industry ConferencesFebruary 25th, 2021
- Synaptogenix to Participate in the Winter Wonderland - Best Ideas from the Buy-Side ConferenceFebruary 12th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
